Unum Therapeutics Inc. (UMRX): Price and Financial Metrics


Unum Therapeutics Inc. (UMRX)

Today's Latest Price: $0.77 USD

0.01 (0.76%)

Updated Feb 19 6:55pm

Add UMRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

UMRX Stock Summary

  • UMRX's went public 1.9 years ago, making it older than merely 3.98% of listed US stocks we're tracking.
  • Of note is the ratio of Unum Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 8.92% of US stocks have a lower such ratio.
  • In terms of volatility of its share price, UMRX is more volatile than 96.34% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Unum Therapeutics Inc, a group of peers worth examining would be ARDS, PTI, GRTS, ALPN, and NVAX.
  • Visit UMRX's SEC page to see the company's official filings. To visit the company's web site, go to www.unumrx.com.
UMRX Daily Price Range
UMRX 52-Week Price Range

UMRX Stock Price Chart More Charts


UMRX Price/Volume Stats

Current price $0.77 52-week high $4.87
Prev. close $0.77 52-week low $0.48
Day low $0.76 Volume 106,500
Day high $0.80 Avg. volume 247,124
50-day MA $0.79 Dividend yield N/A
200-day MA $1.71 Market Cap 23.61M

Unum Therapeutics Inc. (UMRX) Company Bio


Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company’s product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is based in Cambridge, Massachusetts.


UMRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

UMRX Latest Social Stream


Loading social stream, please wait...

View Full UMRX Social Stream

UMRX Price Returns

1-mo -26.85%
3-mo 30.51%
6-mo -54.97%
1-year -81.40%
3-year N/A
5-year N/A
YTD 6.91%
2019 -83.63%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5547 seconds.